These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 25240475)
1. Lessons from the atomic bomb about secondary MDS. Hata T; Imanishi D; Miyazaki Y Curr Hematol Malig Rep; 2014 Dec; 9(4):407-11. PubMed ID: 25240475 [TBL] [Abstract][Full Text] [Related]
2. Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki. Matsuo M; Iwanaga M; Kondo H; Soda M; Jo T; Horio K; Takasaki Y; Kawaguchi Y; Tsushima H; Imaizumi Y; Imanishi D; Taguchi J; Sawayama Y; Hata T; Miyazaki Y Cancer Sci; 2016 Oct; 107(10):1484-1491. PubMed ID: 27487572 [TBL] [Abstract][Full Text] [Related]
3. Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. Tsushima H; Iwanaga M; Miyazaki Y Int J Hematol; 2012 Mar; 95(3):232-8. PubMed ID: 22370711 [TBL] [Abstract][Full Text] [Related]
4. Genome analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. Taguchi M; Mishima H; Shiozawa Y; Hayashida C; Kinoshita A; Nannya Y; Makishima H; Horai M; Matsuo M; Sato S; Itonaga H; Kato T; Taniguchi H; Imanishi D; Imaizumi Y; Hata T; Takenaka M; Moriuchi Y; Shiraishi Y; Miyano S; Ogawa S; Yoshiura KI; Miyazaki Y Haematologica; 2020; 105(2):358-365. PubMed ID: 31101757 [TBL] [Abstract][Full Text] [Related]
5. Impact of Nagasaki atomic bomb exposure on myelodysplastic syndrome patients who are treated with azacitidine. Jo T; Horio K; Shigematsu K Anticancer Res; 2015 May; 35(5):2929-33. PubMed ID: 25964578 [TBL] [Abstract][Full Text] [Related]
6. [Radiation-induced and therapy-related AML/MDS]. Inaba T Nihon Rinsho; 2009 Oct; 67(10):1880-3. PubMed ID: 19860183 [TBL] [Abstract][Full Text] [Related]
8. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. Iwanaga M; Hsu WL; Soda M; Takasaki Y; Tawara M; Joh T; Amenomori T; Yamamura M; Yoshida Y; Koba T; Miyazaki Y; Matsuo T; Preston DL; Suyama A; Kodama K; Tomonaga M J Clin Oncol; 2011 Feb; 29(4):428-34. PubMed ID: 21149671 [TBL] [Abstract][Full Text] [Related]
9. Chromosomal analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. Horai M; Satoh S; Matsuo M; Iwanaga M; Horio K; Jo T; Takasaki Y; Kawaguchi Y; Tsushima H; Yoshida S; Taguchi M; Itonaga H; Sawayama Y; Taguchi J; Imaizumi Y; Hata T; Moriuchi Y; Haase D; Yoshiura KI; Miyazaki Y Br J Haematol; 2018 Feb; 180(3):381-390. PubMed ID: 29265181 [TBL] [Abstract][Full Text] [Related]
12. Therapy-related myelodysplastic syndrome. Candelaria M; Dueñas-Gonzalez A Expert Opin Drug Saf; 2015 May; 14(5):655-65. PubMed ID: 25675961 [TBL] [Abstract][Full Text] [Related]
13. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Kurotaki H; Tsushima Y; Nagai K; Yagihashi S Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673 [TBL] [Abstract][Full Text] [Related]
14. [Epidemiology of leukemia and MDS among atomic bomb survivors in Hiroshima and Nagasaki suggests how abnormal epigenetic regulation contributes to leukemogenesis]. Inaba T Rinsho Ketsueki; 2009 Oct; 50(10):1548-52. PubMed ID: 19915365 [No Abstract] [Full Text] [Related]
15. Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome. Chung YJ; Khawaja G; Wolcott KM; Aplan PD J Vis Exp; 2018 Oct; (140):. PubMed ID: 30346380 [TBL] [Abstract][Full Text] [Related]
16. Molecular pathogenesis and targets for therapy in myelodysplastic syndrome (MDS) and MDS-related leukemias. Karp JE Curr Opin Oncol; 1998 Jan; 10(1):3-9. PubMed ID: 9466478 [TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. Nardi V; Winkfield KM; Ok CY; Niemierko A; Kluk MJ; Attar EC; Garcia-Manero G; Wang SA; Hasserjian RP J Clin Oncol; 2012 Jul; 30(19):2340-7. PubMed ID: 22585703 [TBL] [Abstract][Full Text] [Related]
18. High frequency of AML1/RUNX1 point mutations in radiation-associated myelodysplastic syndrome around Semipalatinsk nuclear test site. Zharlyganova D; Harada H; Harada Y; Shinkarev S; Zhumadilov Z; Zhunusova A; Tchaizhunusova NJ; Apsalikov KN; Kemaikin V; Zhumadilov K; Kawano N; Kimura A; Hoshi M J Radiat Res; 2008 Sep; 49(5):549-55. PubMed ID: 18724045 [TBL] [Abstract][Full Text] [Related]
19. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566 [TBL] [Abstract][Full Text] [Related]
20. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Harada H; Harada Y; Tanaka H; Kimura A; Inaba T Blood; 2003 Jan; 101(2):673-80. PubMed ID: 12393679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]